Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGEN NASDAQ:DYAI NASDAQ:GNLX NASDAQ:HURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$1.34-4.3%$1.49$1.13▼$2.66$119.58M2.58232,459 shs631,966 shsDYAIDyadic International$0.97-2.3%$0.95$0.71▼$2.20$34.99M0.94117,370 shs47,279 shsGNLXGenelux$3.95+8.2%$3.44$1.95▼$5.89$149.20M-0.33129,161 shs294,287 shsHURATuHURA Biosciences$2.50-3.5%$2.67$1.80▼$8.40$125.13M-0.1246,559 shs138,253 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen0.00%-6.29%-6.29%-18.79%-31.98%DYAIDyadic International0.00%+6.25%+29.21%+3.97%-22.02%GNLXGenelux0.00%+17.21%+10.96%+22.29%+61.89%HURATuHURA Biosciences0.00%-1.96%-18.30%-2.72%+249,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$1.34-4.3%$1.49$1.13▼$2.66$119.58M2.58232,459 shs631,966 shsDYAIDyadic International$0.97-2.3%$0.95$0.71▼$2.20$34.99M0.94117,370 shs47,279 shsGNLXGenelux$3.95+8.2%$3.44$1.95▼$5.89$149.20M-0.33129,161 shs294,287 shsHURATuHURA Biosciences$2.50-3.5%$2.67$1.80▼$8.40$125.13M-0.1246,559 shs138,253 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen0.00%-6.29%-6.29%-18.79%-31.98%DYAIDyadic International0.00%+6.25%+29.21%+3.97%-22.02%GNLXGenelux0.00%+17.21%+10.96%+22.29%+61.89%HURATuHURA Biosciences0.00%-1.96%-18.30%-2.72%+249,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGENCompugen 3.00Buy$4.00198.51% UpsideDYAIDyadic International 3.00Buy$6.00520.54% UpsideGNLXGenelux 3.00Buy$20.33414.77% UpsideHURATuHURA Biosciences 3.40Buy$12.67406.67% UpsideCurrent Analyst Ratings BreakdownLatest DYAI, HURA, CGEN, and GNLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025DYAIDyadic InternationalCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy7/23/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/23/2025HURATuHURA BiosciencesBrookline Capital ManagementSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGENCompugen$27.86M4.29N/AN/A$0.62 per share2.16DYAIDyadic International$3.42M10.23N/AN/A$0.08 per share12.09GNLXGeneluxN/AN/AN/AN/A$0.76 per shareN/AHURATuHURA BiosciencesN/AN/AN/AN/A$0.34 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGENCompugen-$14.23M-$0.22N/AN/AN/A-87.45%-34.77%-16.82%11/11/2025 (Estimated)DYAIDyadic International-$5.81M-$0.19N/AN/AN/A-134.84%-355.39%-60.66%11/11/2025 (Estimated)GNLXGenelux-$29.87M-$0.86N/AN/AN/AN/A-107.47%-83.14%11/13/2025 (Estimated)HURATuHURA Biosciences-$21.68MN/A0.00∞N/AN/A-248.79%-150.83%10/6/2025 (Estimated)Latest DYAI, HURA, CGEN, and GNLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025HURATuHURA Biosciences-$0.14-$0.21-$0.07-$0.21N/AN/A8/13/2025Q2 2025DYAIDyadic International-$0.06-$0.06N/A-$0.06$0.60 million$0.97 million8/7/2025Q2 2025GNLXGenelux-$0.22-$0.20+$0.02-$0.20N/AN/A8/6/2025Q2 2025CGENCompugen-$0.07-$0.08-$0.01-$0.08$3.95 million$1.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGENCompugenN/AN/AN/AN/AN/ADYAIDyadic InternationalN/AN/AN/AN/AN/AGNLXGeneluxN/AN/AN/AN/AN/AHURATuHURA BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGENCompugenN/A4.744.74DYAIDyadic International5.402.022.02GNLXGeneluxN/A4.184.18HURATuHURA BiosciencesN/A0.830.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGENCompugen12.22%DYAIDyadic International27.95%GNLXGenelux37.33%HURATuHURA Biosciences0.62%Insider OwnershipCompanyInsider OwnershipCGENCompugen9.50%DYAIDyadic International29.50%GNLXGenelux8.80%HURATuHURA Biosciences0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGENCompugen7089.24 million80.76 millionOptionableDYAIDyadic International736.19 million25.51 millionOptionableGNLXGenelux1037.77 million34.45 millionNot OptionableHURATuHURA BiosciencesN/A50.05 million49.95 millionN/ADYAI, HURA, CGEN, and GNLX HeadlinesRecent News About These CompaniesBrokerages Set TuHURA Biosciences, Inc. (NASDAQ:HURA) Target Price at $12.67September 10, 2025 | americanbankingnews.comTuHURA Biosciences, Inc. (NASDAQ:HURA) Given Average Rating of "Buy" by AnalystsSeptember 8, 2025 | marketbeat.comTuHURA Biosciences (NASDAQ:HURA) Downgraded by Wall Street Zen to "Sell"September 1, 2025 | marketbeat.comTuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment ConferenceAugust 20, 2025 | prnewswire.comTuHURA Biosciences (NASDAQ:HURA) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPSAugust 18, 2025 | marketbeat.comTuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate UpdateAugust 14, 2025 | prnewswire.comTuHURA Biosciences files to sell 4.76M shares of common stock for holdersAugust 12, 2025 | msn.comTuHURA Biosciences, Inc.'s (NASDAQ:HURA) last week's 11% decline must have disappointed retail investors who have a significant stakeAugust 12, 2025 | finance.yahoo.comTuHURA Biosciences, Inc. Common Stock (HURA) Insider ActivityJuly 14, 2025 | nasdaq.comTuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - Seeking AlphaJuly 3, 2025 | seekingalpha.comTuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - MorningstarJuly 3, 2025 | morningstar.comMTuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® IndexesJuly 1, 2025 | finance.yahoo.comTuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® IndexesJuly 1, 2025 | prnewswire.comTuHURA Biosciences, Inc.: TuHURA Biosciences Completes Acquisition of KinetaJune 30, 2025 | finanznachrichten.deTuHURA Biosciences Completes Acquisition of KinetaJune 30, 2025 | prnewswire.comTuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals - MorningstarJune 25, 2025 | morningstar.comMTuHURA initiates phase 3 trial for cancer immunotherapy drugJune 25, 2025 | uk.investing.comTuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or ...June 25, 2025 | morningstar.comMTuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell CarcinomaJune 24, 2025 | prnewswire.comTuhura Biosciences Surges After-Hours As Investors Bet On Kineta Merger, Cancer Drug PipelineJune 23, 2025 | msn.comTuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related ProposalsJune 23, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDYAI, HURA, CGEN, and GNLX Company DescriptionsCompugen NASDAQ:CGEN$1.34 -0.06 (-4.29%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.37 +0.03 (+2.24%) As of 05:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Dyadic International NASDAQ:DYAI$0.97 -0.02 (-2.30%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$0.96 0.00 (-0.20%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.Genelux NASDAQ:GNLX$3.95 +0.30 (+8.22%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.95 0.00 (0.00%) As of 05:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.TuHURA Biosciences NASDAQ:HURA$2.50 -0.09 (-3.47%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.52 +0.02 (+1.00%) As of 05:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
